For Caucasian women, the QCT (quantitative CT) lumbar spine (LS) bone mineral density (BMD) cutpoint value for classifying osteoporosis is 80 mg/ml. At the age of approximate 78 years, US Caucasian women QCT LS BMD population mean is 80 mg/ml, while that of Chinese women and Japanese women is around 50 mg/ml. Correlation analyses show, for Chinese women and Japanese women, QCT LS BMD of 45 mg/ml corresponds to the dual-energy X-ray absorptiometry cutpoint value for classifying osteoporosis. For Chinese and Japanese women, if QCT LS BMD 80 mg/ml is used as the threshold to classify osteoporosis, then the specificity of classifying subjects with vertebral fragility fracture into the osteoporotic group is low, whereas threshold of 45 mg/ml approximately achieve a similar separation for women with and without vertebral fragility fracture as the reports for Caucasian women. Moreover, by using 80mg/ml as the cutpoint value, LS QCT leads to excessively high prevalence of osteoporosis for Chinese women, with the discordance between hip dual-energy X-ray absorptiometry and LS QCT measures far exceeding expectation. Considering the different bone properties and the much lower prevalence of fragility fractures in the East Asian women compared with Caucasians, we argue that the QCT cutpoint value for classifying osteoporosis among older East Asian women will be close to and no more than 50 mg/ml LS BMD. We suggest that it is also imperative the QCT osteoporosis classification criterion for East Asian male LS, and male and female hips be re-examined.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00256-024-04632-4 | DOI Listing |
Alzheimers Dement
December 2024
Centre for Studies on Prevention of Alzheimer's disease (StoP‐AD Centre), Douglas Mental Health Institute, Montreal, QC, Canada
Background: For medical purposes, amyloid‐beta (Aβ) and tau biomarkers are typically dichotomized into positive (+) and negative (‐) status to define individuals with Alzheimer’s disease (AD) pathology. Nevertheless, such AD proteinopathies start accumulating years before reaching clinically‐defined abnormality thresholds. We examined longitudinal change in PET Aβ and tau in cognitively unimpaired (CU) individuals; then we explored their baseline plasma levels and demographic characteristics.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA
Background: While the cerebrospinal fluid (CSF) biomarkers β‐amyloid 1‐42 (Aβ), β‐amyloid 1‐40 (Aβ), total tau (t‐tau), and phosphorylated tau 181 (p‐tau) can detect Alzheimer’s disease (AD) pathology during life, there is a need to evaluate CSF cutpoints for specific application in Lewy body spectrum disorders (LBSD) in order to maximize detection to AD co‐pathology. Using the Fujirebio LUMIPULSE G, we developed LBSD‐derived cutpoints for CSF biomarkers and their ratios (Aβ/Aβ, p‐tau/Aβ, t‐tau/Aβ) to determine which best discriminates αSyn with AD (αSyn+AD) from αSyn without (αSyn). We compared our LBSD‐derived cutpoints to the established AD‐derived cutpoints.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Department of Neurosciences, University of California San Diego, La Jolla, CA, USA
Background: In Parkinson’s disease (PD), concomitant Alzheimer’s disease (AD) pathologic change (ADNC) is common and results in altered motor and cognitive phenotypes. However, detection of PD with AD (PD+AD) using biofluid markers is challenging. While decreased cerebrospinal fluid (CSF) β‐amyloid 1‐42 (Aβ) strongly reflects β‐amyloid burden, PD subjects typically harbor lower CSF phosphorylated tau 181 (p‐tau) and total tau (t‐tau) levels than healthy controls, which complicates detection of tau tangles and neurodegeneration.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Emory University School of Medicine, Atlanta, GA, USA
Background: Plasma pTau217 detects AD pathology and show longitudinal changes dependent on baseline pathology. However, previous studies have been restricted to cohorts with limited diversity. We evaluated performance of plasma pTau217 in detecting AD and predicting disease progression in a diverse cohort from the Emory Goizueta ADRC.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Eli Lilly and Company, Indianapolis, IN, USA
Background: Blood‐based biomarkers have significant potential to aid in the diagnosis of Alzheimer’s disease (AD), providing a more accessible option than cerebrospinal fluid testing or positron emission tomography (PET). This study evaluated performance of a plasma P‐tau217 immunoassay for identifying AD pathology as detected by amyloid or tau PET.
Method: Plasma samples from screened participants from the donanemab Phase 3 trial (NCT04437511) were analyzed using a chemiluminescent immunoassay for plasma P‐tau217 on the Quanterix SP‐X platform.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!